Revance Therapeutics, Inc. ( RVNC ) Reports Q3 Loss, Lags Revenue Estimates
Revance Therapeutics (RVNC) delivered earnings and revenue surprises of -5.71% and 11.60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
| Ticker |
Sentiment |
Impact |
|
CDMO
|
Neutral
|
21 %
|
|
RVNC
|
Neutral
|
40 %
|
